Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7092-7092
Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e18079-e18079